

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Assays &amp; screens</b>			
Proteomics profiling for acute myeloid leukemia (AML)	<p>Array studies suggest that proteomic profiling of blood samples may be a useful prognostic tool for AML. Using reverse phase protein arrays (RPPA), researchers identified seven protein expression signature groups with prognostic value in bone marrow from 256 AML patients. Expression patterns in the signature groups were associated with favorable, intermediate or unfavorable clinical outcomes as defined by rates of complete response, relapse and survival, respectively, and the patterns were mirrored in blood samples from the same patients. Next steps include validating the prognostic value of proteomic profiling in additional AML patient cohorts and increasing the number of proteins measured.</p> <p><i>SciBX</i> 1(39); doi:10.1038/scibx.2008.959 Published online Oct. 30, 2008</p>	Patent application filed for use in clustering leukemia cases and for prognostic and therapeutic guidance	<p>Kornblau, S.M. <i>et al. Blood</i>; published online Oct. 7, 2008; doi:10.1182/blood-2007-10-119438 <b>Contact:</b> Steven M. Kornblau, University of Texas M.D. Anderson Cancer Center, Houston, Texas e-mail: <a href="mailto:skornblau@mdanderson.org">skornblau@mdanderson.org</a></p>